1350653-20-1 Usage
Description
Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator that enhances the cyclic guanosine monophosphate (GMP) production pathway. It works by directly stimulating soluble guanylate cyclase activity and sensitizing soluble guanylate cyclase to endogenous nitric oxide (NO). This medication was initially developed for its potential to reduce mortality and morbidity associated with chronic heart failure with reduced ejection fraction.
Uses
Used in Heart Failure Treatment:
Vericiguat is used as a treatment for heart failure, specifically targeting the cyclic guanosine monophosphate (cGMP) pathway. By increasing the enzymatic activity of sGC to generate cGMP independently of NO and enhancing sGC sensitivity to endogenous NO, vericiguat helps improve the condition of patients with heart failure.
Used in Clinical Trials:
Vericiguat has been tested in clinical trials, such as the SOCRATES-REDUCED phase II dose-finding trial for heart failure with reduced ejection fraction (HF-rEF). Although the primary endpoint, change in NTproBNP over 12 weeks, was not statistically significant compared to placebo, a secondary exploratory analysis suggested a dose-response relationship in which higher doses of vericiguat were associated with greater reductions in NTproBNP levels.
Clinical Use
Vericiguat was advanced to clinical evaluation, as an oral therapy for chronic heart failure, either with reduced ejection fraction (HFrEF), or preserved EF (HFpEF). In mid-June 2020 Merck announced that the FDA had granted priority review status to vericiguat and based on this. The FDA approved vericiguat in January 2021, to reduce the risk of cardiovascular death, heart failure re-hospitalisation, or the requirement for outpatient intravenous diuretics, in patients with symptomatic chronic heart failure and ejection fraction less than 45%. This approval was based on efficacy data arising from the Phase 3 trial NCT02861534 (a.k.a. the VICTORIA trial).
Check Digit Verification of cas no
The CAS Registry Mumber 1350653-20-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,0,6,5 and 3 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1350653-20:
(9*1)+(8*3)+(7*5)+(6*0)+(5*6)+(4*5)+(3*3)+(2*2)+(1*0)=131
131 % 10 = 1
So 1350653-20-1 is a valid CAS Registry Number.
1350653-20-1Relevant articles and documents
PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE
-
Page/Page column 64-65, (2022/01/05)
The present application relates to a novel and efficient process with high yield for preparing methyl {4,6- diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate of the formula (I) in the crystalline form of modification I, wherein the x-ray diffractogram of the compound of the formula (I) in modification I exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 22.7, in very high purity which is significantly more cost-effective than the process known from the art and can be performed in customary pilot- and production plant-equipment (stirred tank/devices for isolation).
BICYCLIC AZA HETEROCYCLES, AND USE THEREOF
-
, (2014/06/11)
The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
-
Paragraph 0229; 0235; 0236, (2013/06/26)
The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for tr
